Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction

[Image: see text] Myeloperoxidase is a promising therapeutic target for treatment of patients suffering from heart failure with preserved ejection fraction (HFpEF). We aimed to discover a covalent myeloperoxidase inhibitor with high selectivity for myeloperoxidase over thyroid peroxidase, limited pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Inghardt, Tord, Antonsson, Thomas, Ericsson, Cecilia, Hovdal, Daniel, Johannesson, Petra, Johansson, Carina, Jurva, Ulrik, Kajanus, Johan, Kull, Bengt, Michaëlsson, Erik, Pettersen, Anna, Sjögren, Tove, Sörensen, Henrik, Westerlund, Kristina, Lindstedt, Eva-Lotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469207/
https://www.ncbi.nlm.nih.gov/pubmed/36005476
http://dx.doi.org/10.1021/acs.jmedchem.1c02141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469207/
https://www.ncbi.nlm.nih.gov/pubmed/36005476
http://dx.doi.org/10.1021/acs.jmedchem.1c02141

Ejemplares similares